AC Immune SA (ACIU) Stock Forecast, Price Target & Predictions
ACIU Stock Forecast
AC Immune SA stock forecast is as follows: an average price target of $9.00 (represents a 160.12% upside from ACIU’s last price of $3.46) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ACIU Price Target
The average price target for AC Immune SA (ACIU) is $9.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $8.00. This represents a potential 160.12% upside from ACIU's last price of $3.46.
ACIU Analyst Ratings
According to 2 Wall Street analysts, AC Immune SA's rating consensus is 'Buy'. The analyst rating breakdown for ACIU stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AC Immune SA Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 30, 2024 | Thomas Shrader | BTIG | $8.00 | $3.97 | 101.51% | 131.21% |
| Jul 11, 2022 | - | Leerink Partners | $10.00 | $3.35 | 198.51% | 189.02% |
The latest AC Immune SA stock forecast, released on May 30, 2024 by Thomas Shrader from BTIG, set a price target of $8.00, which represents a 101.51% increase from the stock price at the time of the forecast ($3.97), and a 131.21% increase from ACIU last price ($3.46).
AC Immune SA Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $3.46 | $3.46 | $3.46 |
| Upside/Downside | -100.00% | -100.00% | 131.21% |
In the current month, the average price target of AC Immune SA stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AC Immune SA's last price of $3.46. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 30, 2024 | BTIG | - | Buy | Initialise |
| Jul 11, 2022 | SVB Leerink | Outperform | Outperform | Hold |
AC Immune SA's last stock rating was published by BTIG on May 30, 2024. The company Initialise its ACIU rating from "null" to "Buy".
AC Immune SA Financial Forecast
AC Immune SA Revenue Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.00K | $3.93M |
| Avg Forecast | $180.99M | $3.44M | $1.18M | $90.89M | $5.34M | $15.29M | $50.07M | $2.50M | $1.60M | $349.15K |
| High Forecast | $180.99M | $3.44M | $1.59M | $90.89M | $5.34M | $16.56M | $50.07M | $2.50M | $1.60M | $349.15K |
| Low Forecast | $180.99M | $3.44M | $440.54K | $90.89M | $5.34M | $14.02M | $50.07M | $2.50M | $1.60M | $349.15K |
| # Analysts | - | 2 | 3 | 2 | 1 | 2 | 1 | 1 | - | - |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 11.27% |
AC Immune SA's average Quarter revenue forecast for Jun 23 based on 1 analysts is $2.50M, with a low forecast of $2.50M, and a high forecast of $2.50M. ACIU's average Quarter revenue forecast represents a 250007.40% increase compared to the company's last Quarter revenue of $1.00K (Dec 22).
AC Immune SA EBITDA Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 2 | 3 | 2 | 1 | 2 | 1 | 1 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | $-18.03M | $-12.87M |
| Avg Forecast | $-57.23M | $-1.09M | $-372.93K | $-28.74M | $-1.69M | $-4.84M | $-15.83M | $-790.92K | $-505.79K | $-16.69M |
| High Forecast | $-57.23M | $-1.09M | $-139.31K | $-28.74M | $-1.69M | $-4.43M | $-15.83M | $-790.92K | $-505.79K | $-13.35M |
| Low Forecast | $-57.23M | $-1.09M | $-501.53K | $-28.74M | $-1.69M | $-5.24M | $-15.83M | $-790.92K | $-505.79K | $-20.02M |
| Surprise % | - | - | - | - | - | - | - | - | 35.66% | 0.77% |
undefined analysts predict ACIU's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than AC Immune SA's previous annual EBITDA (undefined) of $NaN.
AC Immune SA Net Income Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 2 | 3 | 2 | 1 | 2 | 1 | 1 | - | - |
| Net Income | - | - | - | - | - | - | - | - | $-18.75M | $-13.52M |
| Avg Forecast | - | $-18.78M | $-21.02M | $47.36M | $-13.48M | $-9.64M | $3.01M | $-19.37M | $-24.52M | $-17.45M |
| High Forecast | - | $-18.78M | $-21.02M | $47.36M | $-13.48M | $-2.75M | $3.01M | $-19.37M | $-24.52M | $-13.96M |
| Low Forecast | - | $-18.78M | $-21.98M | $47.36M | $-13.48M | $-16.52M | $3.01M | $-19.37M | $-24.52M | $-20.94M |
| Surprise % | - | - | - | - | - | - | - | - | 0.76% | 0.77% |
AC Immune SA's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACIU's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
AC Immune SA SG&A Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 2 | 3 | 2 | 1 | 2 | 1 | 1 | - | - |
| SG&A | - | - | - | - | - | - | - | - | $-2.25M | $3.27M |
| Avg Forecast | $236.38M | $4.49M | $1.54M | $118.71M | $6.97M | $19.97M | $65.39M | $3.27M | $2.09M | $456.01K |
| High Forecast | $236.38M | $4.49M | $2.07M | $118.71M | $6.97M | $21.63M | $65.39M | $3.27M | $2.09M | $456.01K |
| Low Forecast | $236.38M | $4.49M | $575.37K | $118.71M | $6.97M | $18.31M | $65.39M | $3.27M | $2.09M | $456.01K |
| Surprise % | - | - | - | - | - | - | - | - | -1.08% | 7.18% |
AC Immune SA's average Quarter SG&A projection for Dec 22 is $2.09M, based on 0 Wall Street analysts, with a range of $2.09M to $2.09M. The forecast indicates a -36.20% fall compared to ACIU last annual SG&A of $3.27M (Sep 22).
AC Immune SA EPS Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 2 | 3 | 2 | 1 | 2 | 1 | 1 | - | - |
| EPS | - | - | - | - | - | - | - | - | $-0.22 | $-0.16 |
| Avg Forecast | - | $-0.19 | $-0.21 | $0.48 | $-0.14 | $-0.10 | $0.03 | $-0.19 | $-0.25 | $-0.23 |
| High Forecast | - | $-0.19 | $-0.21 | $0.48 | $-0.14 | $-0.03 | $0.03 | $-0.19 | $-0.25 | $-0.23 |
| Low Forecast | - | $-0.19 | $-0.22 | $0.48 | $-0.14 | $-0.17 | $0.03 | $-0.19 | $-0.25 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - | - | 0.89% | 0.70% |
According to undefined Wall Street analysts, AC Immune SA's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACIU previous annual EPS of $NaN (undefined).
AC Immune SA Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| IVVD | Invivyd | $1.11 | $9.50 | 755.86% | Buy |
| ANTX | AN2 Therapeutics | $1.06 | $8.75 | 725.47% | Buy |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| OPT | Opthea | $3.41 | $14.00 | 310.56% | Buy |
| PEPG | PepGen | $9.12 | $29.50 | 223.46% | Buy |
| BDTX | Black Diamond Therapeutics | $4.83 | $14.75 | 205.38% | Buy |
| RGNX | REGENXBIO | $12.95 | $38.00 | 193.44% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ACRV | Acrivon Therapeutics | $7.60 | $22.00 | 189.47% | Buy |
| FDMT | 4D Molecular Therapeutics | $16.16 | $44.57 | 175.80% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| ACIU | AC Immune SA | $3.46 | $9.00 | 160.12% | Buy |
| STOK | Stoke Therapeutics | $15.12 | $33.75 | 123.21% | Buy |
| PHVS | Pharvaris | $20.25 | $38.50 | 90.12% | Buy |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| ABEO | Abeona Therapeutics | $5.46 | $6.00 | 9.89% | Buy |
ACIU Forecast FAQ
Is AC Immune SA a good buy?
Yes, according to 2 Wall Street analysts, AC Immune SA (ACIU) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ACIU's total ratings.
What is ACIU's price target?
AC Immune SA (ACIU) average price target is $9 with a range of $8 to $10, implying a 160.12% from its last price of $3.46. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AC Immune SA stock go up soon?
According to Wall Street analysts' prediction for ACIU stock, the company can go up by 160.12% (from the last price of $3.46 to the average price target of $9), up by 189.02% based on the highest stock price target, and up by 131.21% based on the lowest stock price target.
Can AC Immune SA stock reach $5?
ACIU's average twelve months analyst stock price target of $9 supports the claim that AC Immune SA can reach $5 in the near future.
What are AC Immune SA's analysts' financial forecasts?
AC Immune SA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $100.85M (high $101.26M, low $100.11M), average EBITDA is $-31.892M (high $-31.659M, low $-32.021M), average net income is $-5.93M (high $-5.93M, low $-6.885M), average SG&A $131.72M (high $132.25M, low $130.75M), and average EPS is $-0.0596 (high $-0.0596, low $-0.0692). ACIU's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $180.99M (high $180.99M, low $180.99M), average EBITDA is $-57.235M (high $-57.235M, low $-57.235M), average net income is $0 (high $0, low $0), average SG&A $236.38M (high $236.38M, low $236.38M), and average EPS is $0 (high $0, low $0).
Did the ACIU's actual financial results beat the analysts' financial forecasts?
Based on AC Immune SA's last annual report (Dec 2022), the company's revenue was $3.94M, beating the average analysts forecast of $1.95M by 101.94%. Apple's EBITDA was $-70.778M, beating the average prediction of $-17.192M by 311.69%. The company's net income was $-70.753M, beating the average estimation of $-41.969M by 68.59%. Apple's SG&A was $15.79M, beating the average forecast of $2.54M by 520.41%. Lastly, the company's EPS was $-0.85, beating the average prediction of $-0.476 by 78.67%. In terms of the last quarterly report (Dec 2022), AC Immune SA's revenue was $1K, missing the average analysts' forecast of $1.6M by -99.94%. The company's EBITDA was $-18.034M, beating the average prediction of $-506K by 3465.53%. AC Immune SA's net income was $-18.749M, missing the average estimation of $-24.519M by -23.53%. The company's SG&A was $-2.246M, missing the average forecast of $2.09M by -207.52%. Lastly, the company's EPS was $-0.22, missing the average prediction of $-0.246 by -10.68%